Bortezomib Completed Phase 2 Trials for Metastatic / Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01633645Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer